SOHM Acquires ABBIE
On September 25, SOHM, Inc. announced that it acquired ABBIE from CGA 369 for $10 million. ABBIE is a gene-editing platform which can deliver genetic payloads using non-viral vectors. ABBIE uses targeted integration to insert larger DNA sequences, including full genes, into a desired loci of the target cell’s genome. ABBIE will be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering technologies. SOHM, is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM’s... Read More »
Berkeley Biologics Acquires Elutia’s Orthobiologics Business Unit
Elutia Inc. (previously known as Aziyo Biologics, Inc.) announced on September 18 that it divested its Orthobiologics business unit to Berkeley Biologics LLC. Mizuho Securities USA LLC acted as advisor to Elutia. According to data captured in the LevinPro HC database, this transaction marks the 110th Biotechnology transaction of the year. Elutia will receive cash proceeds of up to $35 million, comprising an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period. The transaction is expected to close in the fourth quarter of 2023. Orthobiologics are therapies that can be used by orthopaedic... Read More »
Sagaliam Acquisition Corp. Acquires Biogenysis and Virogentics
Enzolytics, Inc. announced on September 18 that it sold two of its wholly owned subsidiaries, Biogenysis, Inc. and Virogentics, Inc., to Sagaliam Acquisition Corp. in a transaction valued at $450 million. Enzolytics is a Texas-based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. Biogenysis uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus... Read More »
Agilent Technologies Divests Resolution Bioscience
Agilent Technologies, Inc. announced it is selling Resolution Bioscience Inc. to Exact Sciences Corp. Financial terms of the agreement were not disclosed and are not material to either party. According to data captured in the LevinPro HC database, this transaction represents the 108th Biotechnology acquisition of 2023. Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis. Exact Sciences is a molecular diagnostics company which focuses on the early... Read More »
Agios Pharmaceuticals Acquires Alnylam’s siRNA Blood Disease Program
Agios Pharmaceuticals Inc. announced its acquisition of Alnylam Pharmaceuticals, Inc.’s siRNA blood disease program targeting TMPRSS6, a gene that makes protein. According to data captured in the LevinPro HC database, this transaction marks the 105th Biotechnology acquisition in 2023. Alnylam is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002. According to its most recent financial report, the company achieved net product revenues of $894 million during FY 2022. Agios is the pioneering leader in pyruvate kinase (PK) activation... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
